0

Novel Butanehydrazide Derivatives of purine-2,6-dione as Dual PDE4/7 Inhibitors With Potential Anti-Inflammatory Activity: Design, Synthesis and Biological Evaluation

Grażyna Chłoń-Rzepa, Agnieszka Jankowska, Marietta Ślusarczyk, Artur Świerczek, Krzysztof Pociecha, Elżbieta Wyska, Adam Bucki, Alicja Gawalska, Marcin Kołaczkowski, Maciej Pawłowski

Eur J Med Chem. 2018 Feb 25;146:381-394.

PMID: 29407965

Abstract:

A novel butanehydrazide derivatives of purine-2,6-dione designed using a ligand-based approach were synthesized and their in vitro activity against both PDE4B and PDE7A isoenzymes was assessed. The 7,8-disubstituted purine-2,6-dione derivatives 31, 34, 37, and 40 appeared to be the most potent PDE4/7 inhibitors with IC50 values in the range of that of the reference rolipram and BRL-50481, respectively. Moreover, docking studies explained the importance of N-(2,3,4-trihydroxybenzylidene)butanehydrazide substituent in position 7 of purine-2,6-dione core for dual PDE4/7 inhibitory properties. The inhibition of both the cAMP-specific PDE isoenzymes resulted in a strong anti-TNF-α effect. Compounds 31, 34, and 37 in the in vivo study in rats with LPS-induced endotoxemia decreased the maximum concentration of this proinflammatory cytokine by 53, 84 and 88%, respectively.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP433695364 BRL 50481 BRL 50481 433695-36-4 Price
IAR4245724 PDE7A active rat PDE7A active rat Price
qrcode